News & Events

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

January 12, 2026

Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer

January 5, 2026

Kailera Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

Kailera Therapeutics to Participate in Upcoming November Investor Conferences

November 5, 2025

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

November 4, 2025

Kailera Therapeutics Appoints Frank Clyburn to Board of Directors

November 3, 2025

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

October 21, 2025

Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity

October 14, 2025

Kailera Therapeutics to Participate in Upcoming Investor Conferences

August 27, 2025